Usana Health Sciences, Inc. (USNA) Financials

EPS

Hollow marker is the consensus estimate; filled is the reported figure, colored by beat or miss.

Revenue

Outlined bar is the consensus estimate; solid is reported.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
Q2 26	$0.43	-$0.07	-116.3%	—	$223.3M	—
Q1 26	$0.44	$0.61	+38.6%	—	$250.2M	—
Q4 25	$0.41	$0.6	+46.3%	—	$226.2M	—
Q3 25	-$0.15	-$0.15	0.0%	—	$213.7M	—
Q2 25	$0.54	$0.74	+37.0%	—	$235.8M	—
Q1 25	$0.7	$0.73	+4.3%	—	$249.5M	—
Q4 24	$0.49	$0.64	+30.6%	—	$213.6M	—
Q3 24	$0.49	$0.56	+14.3%	—	$200.2M	—
Q2 24	$0.65	$0.54	-16.9%	—	$212.9M	—
Q1 24	$0.69	$0.86	+24.6%	—	$227.8M	—
Q4 23	$0.52	$0.87	+67.3%	—	$221.1M	—
Q3 23	$0.64	$0.59	-7.8%	—	$213.4M	—
Q2 23	$0.7	$0.89	+27.1%	—	$238.2M	—
Q1 23	$0.77	$0.95	+23.4%	—	$248.4M	—
Q4 22	$0.35	$0.66	+88.6%	—	$228M	—
Q3 22	$0.89	$0.78	-12.4%	—	$233.3M	—

EPS

Reported per-share earnings by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Revenue

Reported revenue by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
FY25	—	$0.59	—	—	$925.3M	—
FY24	—	$2.21	—	—	$854.5M	—
FY23	—	$3.33	—	—	$921M	—
FY22	—	$3.61	—	—	$998.6M

Total revenue

Reported revenue per period; the line is the change from the same period a year earlier, on its own left axis.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	$1B	$1B	$1.2B	$1.1B	$1.1B	$1.2B	$998.6M	$921M	$854.5M	$925.3M
YoY change	+9.54%	+4.09%	+13.6%	-10.8%	+6.95%	+4.57%	-15.8%	-7.77%	-7.22%	+8.28%

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	1B	1B	1.2B	1.1B	1.1B	1.2B	998.6M	921M	854.5M	925.3M
Cost of revenue	180.2M	179.4M	200.7M	187.5M	209.1M	217.9M	193.9M	176.7M	161.2M	200.9M
Gross profit	825.9M	867.9M	988.5M	873.4M	925.5M	968.6M	804.7M	744.3M	693.3M	724.4M
Gross margin	82.1%	82.9%	83.1%	82.3%	81.6%	81.6%	80.6%	80.8%	81.1%	78.3%
Research & development	—	—	—	—	—	—	—	—	—	—
Selling, general & administrative	234.2M	265.1M	275.1M	267.7M	261.2M	279.1M	262.3M	257M	263.3M	337.4M
Operating expenses	687.3M	735.4M	800.2M	727.2M	749M	798.4M	697.1M	651.2M	627M	673.5M
Operating income	138.6M	132.5M	188.4M	146.2M	176.5M	170.2M	107.6M	93.1M	66.3M	50.9M
Operating margin	13.8%	12.7%	15.8%	13.8%	15.6%	14.3%	10.8%	10.1%	7.76%	5.5%
Non-operating income, net	-1.1M	-3K	-1.2M	-335K	-571K	-2M	-2.6M	7K	-1M	-10.9M
Pretax income	138.6M	134.6M	191.5M	150.5M	177.9M	170.6M	108.6M	102.5M	76.4M	41.5M
Income tax	38.5M	72.1M	65.3M	50M	53.3M	54.1M	39.3M	38.7M	34.3M	30.1M
Net income	100M	62.5M	126.2M	100.5M	124.7M	116.5M	69.3M	63.8M	42.1M	11.5M
Net margin	9.94%	5.97%	10.6%	9.48%	11%	9.82%	6.94%	6.93%	4.92%	1.24%
EBITDA	152.5M	150.8M	208.4M	173.6M	201M	192.9M	130.2M	123.1M	98.9M	95.5M
EPS	4.09	2.6	5.36	4.64	5.93	5.99	3.61	3.33	2.21	0.59
Diluted EPS	3.99	2.53	5.12	4.41	5.86	5.73	3.59	3.3	2.19	0.58

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	213.4M	221.1M	227.8M	212.9M	200.2M	213.6M	249.5M	235.8M	213.7M	226.2M	250.2M	223.3M
Cost of revenue	42.5M	42.3M	43.1M	40.3M	39.3M	38.6M	52.4M	50.2M	48.8M	49.4M	59.4M	48.3M
Gross profit	170.8M	178.8M	184.7M	172.5M	161M	175.1M	197.1M	185.7M	164.9M	176.8M	190.8M	174.9M
Gross margin	80.1%	80.9%	81.1%	81.1%	80.4%	82%	79%	78.7%	77.2%	78.2%	76.2%	78.3%
Research & development	—	—	—	—	—	—	—	—	—	—	—	—
Selling, general & administrative	63.3M	58.7M	64.3M	64.3M	61.3M	73.3M	91.4M	81.9M	85.9M	78.1M	88.3M	82.3M
Operating expenses	153.2M	154.5M	160.1M	154.7M	145.4M	166.8M	181.4M	168.9M	163.6M	159.5M	176.9M	165.8M
Operating income	17.6M	24.2M	24.7M	17.8M	15.6M	8.2M	15.7M	16.7M	1.2M	17.2M	13.9M	9.1M
Operating margin	8.25%	11%	10.8%	8.38%	7.79%	3.84%	6.28%	7.09%	0.57%	7.63%	5.54%	4.09%
Non-operating income, net	234K	-368K	-186K	-349K	-86K	-390K	756K	1.7M	41K	-13.4M	1.4M	-28.6M
Pretax income	20.5M	26.6M	27.1M	20.2M	18.6M	10.4M	16.7M	18.8M	1.8M	4.2M	15.5M	-18.9M
Income tax	9.2M	9.8M	10.6M	9.8M	8M	5.9M	7.4M	8.4M	8.5M	5.8M	8.5M	9.1M
Net income	11.3M	16.8M	16.5M	10.4M	10.6M	4.5M	9.3M	10.4M	-6.7M	-1.6M	7M	-28M
Net margin	5.32%	7.58%	7.26%	4.9%	5.3%	2.1%	3.72%	4.43%	-3.12%	-0.71%	2.78%	-12.5%
EBITDA	25.7M	31.6M	32.2M	26M	24.2M	16.4M	27.4M	28.7M	11.4M	14.6M	25.5M	19.4M
EPS	0.59	0.88	0.86	0.55	0.56	0.24	0.49	0.52	-0.36	-0.1	0.41	-1.16
Diluted EPS	0.59	0.87	0.86	0.54	0.56	0.23	0.49	0.52	-0.36	-0.1	0.41	-1.16

P/E

Annual history by fiscal year; click a table row below to chart a different metric.

Current values are trailing twelve months where available, otherwise the latest fiscal year; unreported figures show a dash.

Key stats

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Market cap	1.5B	1.8B	2.8B	1.7B	1.6B	2B	1B	1B	684.2M	358.9M	273.8M
Enterprise value	1.3B	1.5B	2.5B	1.5B	1.3B	1.7B	740.2M	703M	531.5M	220.1M	144M
Shares outstanding	24.5M	24M	23.6M	21.7M	21M	19.4M	19.2M	19.1M	19.1M	18.3M	18.3M

Valuation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
P/E	15	28.4	22	16.9	13	16.8	14.7	16.1	16.3	31.3	27.3
P/S	1.49	1.7	2.33	1.6	1.43	1.65	1.02	1.11	0.8	0.39	0.29
P/B	4.61	4.9	7.09	4.84	3.67	4.97	2.35	2.06	1.17	0.61	0.51
EV/EBITDA	8.67	10.2	12	8.5	6.56	8.97	5.68	5.71	5.38	2.3	1.95
EV/Sales	1.31	1.46	2.1	1.39	1.16	1.46	0.74	0.76	0.62	0.24	0.16
Earnings yield	6.68%	3.52%	4.55%	5.91%	7.69%	5.94%	6.79%	6.22%	6.15%	3.2%	3.66%
FCF yield	6.95%	6.21%	5.07%	6.48%	8.96%	5.53%	9.15%	5.48%	7.44%	2.38%	17.9%
PEG	—	—	—	—	—	—	—	—	—	—	-0.08

Profitability

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Gross margin	82.1%	82.9%	83.1%	82.3%	81.6%	81.6%	80.6%	80.8%	81.1%	78.3%	78.3%
Operating margin	13.8%	12.7%	15.8%	13.8%	15.6%	14.3%	10.8%	10.1%	7.76%	5.5%	4.09%
Net margin	9.94%	5.97%	10.6%	9.48%	11%	9.82%	6.94%	6.93%	4.92%	1.24%	-2.43%
ROE	30.8%	17.2%	32.3%	28.6%	28.2%	29.5%	16%	12.8%	7.17%	1.96%	-5.06%
ROA	21.3%	12%	22.8%	19.4%	19.5%	20.2%	11.6%	10.1%	5.62%	1.54%	3.61%
ROIC	66.9%	53%	109.6%	78%	89.4%	71.6%	44.9%	33.1%	8.43%	3.14%	0%
Return on tangible assets	27.1%	15.1%	27.6%	23.7%	22.9%	24.2%	14%	11.8%	26.9%	5.72%	-12.4%

Financial health

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Current ratio	2.01	2.41	2.64	2.42	2.53	2.27	2.67	3.52	2	2.24	2.66
Quick ratio	1.54	1.96	2.09	1.91	1.99	1.66	2.21	3	1.5	1.45	1.84
Debt / equity	—	—	—	0.02	0.02	0.02	0.02	0.02	0.05	0.03	0
Debt / assets	—	—	—	0.02	0.01	0.01	0.01	0.01	0.04	0.03	0.03
Net debt / EBITDA	—	—	—	-1.3	-1.51	-1.21	-2.16	-2.62	-1.55	-1.45	-2.38
Interest coverage	313.1	2.9K	5.3K	2.3K	352	3K	566.7	392	272.7	50.3	7.16
Effective tax rate	27.8%	53.6%	34.1%	33.2%	29.9%	31.7%	36.2%	37.7%	44.9%	72.4%	100%

Per share

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Revenue per share	41.1	43.6	50.5	49	53.9	61.2	52	48.1	44.8	50.6	49.7
EPS (basic)	4.09	2.6	5.36	4.64	5.93	5.99	3.61	3.33	2.21	0.59	0.59
EPS (diluted)	3.99	2.53	5.12	4.41	5.86	5.73	3.59	3.3	2.19	0.58	-1.18
Book value per share	13.3	15.1	16.6	16.2	21	20.4	22.6	26	30.8	32.1	28.5
FCF per share	4.26	4.6	5.97	5.09	6.91	5.59	4.87	2.94	2.67	0.47	0.86
Cash per share	7.18	10.3	11.8	10.8	14.8	12.4	15	17.3	9.53	8.66	9.12
Capex per share	1.33	0.55	0.47	0.76	0.72	0.66	0.54	0.76	0.53	—	—

Capital allocation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Capex / revenue	3.25%	1.26%	0.93%	1.56%	1.33%	1.07%	1.04%	1.57%	1.17%	—	—
Capex / operating cash flow	22.3%	11.4%	7.24%	13.9%	9.15%	10.7%	10.3%	21.3%	16.2%	—	—
Payout ratio	—	—	—	—	—	—	—	—	—	—	0%

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	$213.4M	$221.1M	$227.8M	$212.9M	$200.2M	$213.6M	$249.5M	$235.8M	$213.7M	$226.2M	$250.2M	$223.3M
YoY change	-8.54%	-3.02%	-8.28%	-10.6%	-6.16%	-3.38%	+9.54%	+10.8%	+6.72%	+5.89%	+0.27%	-5.33%

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash & short-term investments	175.8M	247.1M	277.9M	234.8M	311.9M	239.8M	288.4M	330.4M	181.8M	158.4M
Receivables	—	—	—	—	—	—	—	—	—	—
Inventory	64.8M	62.9M	81.9M	68.9M	90.2M	98.3M	67.1M	61.5M	69.7M	102.6M
Total current assets	277.9M	340.2M	392.3M	329.3M	425.3M	365.1M	384.4M	417.7M	279.2M	288.4M
Property, plant & equipment	30.5M	29.5M	20.7M	24M	20.8M	21M	19.7M	22M	17.9M	15.8M
Goodwill & intangibles	102.1M	105.1M	97.3M	93M	96.3M	96.2M	99.6M	94M	592M	542.2M
Total assets	470.6M	519.3M	554.5M	516.9M	640.9M	577.7M	596.5M	632.8M	748.2M	742.9M
Accounts payable	9M	11.8M	9.9M	12.5M	18.2M	13.5M	11M	10.1M	12M	17.3M
Short-term debt	—	—	—	8.3M	8.6M	7.1M	6.9M	8.1M	29M	19.6M
Total current liabilities	138.5M	141.2M	148.7M	136.1M	168.1M	160.8M	143.8M	118.8M	139.6M	128.6M
Long-term debt	—	—	—	—	—	—	—	—	—	—
Total liabilities	145.4M	156.1M	163.3M	165.2M	199.2M	182.6M	162.1M	135.6M	161.9M	156.6M
Shareholders' equity	325.3M	363.2M	391.1M	351.7M	441.6M	395.1M	434.5M	497.2M	586.3M	586.3M
Total debt	—	—	—	8.3M	8.6M	7.1M	6.9M	8.1M	29M	19.6M
Net debt	—	—	—	-226.5M	-303.3M	-232.8M	-281.5M	-322.4M	-152.8M	-138.7M

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Cash & short-term investments	307.1M	330.4M	328.3M	332.4M	364.9M	181.8M	179.6M	151.3M	145.3M	158.4M	162.8M	168.6M
Receivables	—	—	—	—	—	—	—	—	—	—	9.7M	3.3M
Inventory	60.1M	61.5M	60.9M	61.8M	64M	69.7M	73.6M	83.3M	90.8M	102.6M	96.4M	86.3M
Total current assets	390.5M	417.7M	421.1M	419.1M	451.2M	279.2M	281.4M	261.9M	264.1M	288.4M	294.2M	281.1M
Property, plant & equipment	—	22M	—	—	—	17.9M	—	—	—	15.8M	—	—
Goodwill & intangibles	92.5M	94M	92M	90.9M	92.9M	592M	582.8M	574M	564.9M	542.2M	534.1M	467.5M
Total assets	601.1M	632.8M	629.3M	631.4M	671.3M	748.2M	746.6M	734.5M	726.6M	742.9M	739M	703.2M
Accounts payable	9.3M	10.1M	8.3M	6.6M	7M	12M	14M	17.9M	16.2M	17.3M	16.2M	15.4M
Short-term debt	—	8.1M	1.3M	—	—	29M	23M	—	—	19.6M	14M	—
Total current liabilities	112.6M	118.8M	112.6M	103.9M	114.8M	139.6M	137.4M	121.6M	118.7M	128.6M	117.2M	105.7M
Long-term debt	—	—	—	—	—	—	—	—	—	—	—	—
Total liabilities	130.8M	135.6M	129.3M	119.2M	138.2M	161.9M	162.7M	149M	145M	156.6M	144.2M	132.2M
Shareholders' equity	470.4M	497.2M	500M	512.2M	533.1M	586.3M	583.9M	585.6M	581.6M	586.3M	594.8M	571M
Total debt	—	8.1M	1.3M	—	—	29M	23M	—	—	19.6M	14M	—
Net debt	—	-322.4M	-327M	—	—	-152.8M	-156.6M	—	—	-138.7M	-148.8M	—

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Net income	100M	62.5M	126.2M	100.5M	124.7M	116.5M	69.3M	63.8M	42.1M	11.5M
Depreciation & amortization	13.5M	16.1M	16.8M	23M	22.5M	22.2M	21.4M	20.4M	22.2M	39.7M
Stock-based compensation	16.5M	15.5M	15M	15.5M	14.4M	14.3M	13.3M	14.6M	14.6M	13.8M
Change in working capital	20.2M	2.6M	-6.1M	-16M	5.7M	-30.7M	4.1M	-28.1M	-10.1M	-43.7M
Operating cash flow	146.5M	116M	152.6M	119.5M	164.9M	119.3M	101M	67.9M	62M	22.3M
Capital expenditure	-32.7M	-13.2M	-11.1M	-16.6M	-15.1M	-12.7M	-10.4M	-14.5M	-10M	—
Investing cash flow	-31.9M	-12.9M	-69M	47.5M	-34M	-14.2M	-12.4M	-12M	-213.1M	-207K
Dividends paid	—	—	—	—	—	—	—	—	—	—
Share repurchases	-64.6M	-50M	-105.4M	-150M	-57M	-177.8M	-25.4M	-11.6M	-9.4M	-27.5M
Financing cash flow	-138.6M	-53.8M	-105.3M	-157.1M	-119.4M	-181.4M	-41.1M	-15M	8.1M	-67.2M
Net change in cash	-23.9M	49.3M	-21.7M	9.9M	11.5M	-76.3M	47.5M	41M	-143M	-45.1M
Free cash flow	104.2M	110.6M	140.7M	110.2M	145.3M	108.5M	93.5M	56.1M	50.9M	8.5M

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Net income	11.3M	16.8M	16.5M	10.4M	10.6M	4.5M	9.3M	10.4M	-6.7M	-1.6M	7M	-28M
Depreciation & amortization	5.2M	4.9M	5.1M	5.7M	5.6M	5.9M	10.2M	9.6M	9.6M	10.3M	9.8M	9.2M
Stock-based compensation	3.7M	3.6M	3.7M	3.7M	3.5M	3.6M	2.9M	3.6M	3.6M	3.8M	3.5M	3.4M
Change in working capital	780K	1.7M	-6.4M	-9.9M	7.6M	-1.4M	-9.2M	-4.3M	-11.2M	-19M	-12.2M	10.7M
Operating cash flow	21.8M	28.4M	21.5M	2.5M	28.2M	9.9M	14.5M	12.2M	-2M	-3.4M	9.8M	23.3M
Capital expenditure	-1.5M	-7.3M	-3.2M	-2.7M	-2.3M	-1.8M	-2.8M	—	—	—	—	—
Investing cash flow	-1.5M	-7.3M	-4.1M	-2.7M	-2.3M	-1.8M	-3.9M	0	0	0	0	-917K
Dividends paid	—	—	—	—	—	—	—	—	—	—	—	—
Share repurchases	-11.6M	0	-9.4M	0	0	0	-12.3M	-15.2M	0	0	0	0
Financing cash flow	-11.6M	658K	-11.9M	-1.4M	-75K	22.9M	-14.5M	-63.2M	-979K	11.5M	-7.6M	-33M
Net change in cash	8.7M	21.8M	5.4M	-1.6M	25.7M	31M	-3.8M	-51M	-2.9M	8.1M	2.1M	-10.6M
Free cash flow	20.8M	18.7M	14.5M	5.3M	27.1M	4M	12.7M	7.2M	-5.2M	-6.2M	7.1M	20.2M

Usana Health Sciences, Inc. Financials

EPS

Revenue

Results

EPS

Revenue

Results

Total revenue

Total revenue

Revenue and profits

Condensed income statement

Revenue and profits

Condensed income statement

P/E

Key stats

Valuation

Profitability

Financial health

Per share

Capital allocation

Assets vs. liabilities & equity

Condensed balance sheet

Assets vs. liabilities & equity

Condensed balance sheet

Cash generation and uses

Condensed cash flow statement

Cash generation and uses

Condensed cash flow statement